Enanta Pharmaceuticals Announces Positive Topline Results for …
WEB6 days ago · WATERTOWN, Mass. -- (BUSINESS WIRE)--Sep. 26, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These ...
Enanta Pharmaceuticals Announces Positive Topline Results for …
WEB5 days ago · Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV
Enanta Pharmaceuticals to Provide Updates on its Research and ...
WEBJan 4, 2024 · Enanta is progressing multiple clinical programs targeting populations at high-risk for serious outcomes from RSV infection. Its lead candidate, zelicapavir, an oral, N-protein inhibitor, is...
Enanta Pharmaceuticals Reports Financial Results for its Fiscal …
WEBNov 20, 2023 · Enanta recorded an income tax benefit of $1.4 million for the three months ended September 30, 2023, compared to income tax expense of less than $0.1 million for the three months ended September 30, 2022.
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial ...
WEB5 days ago · Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms while maintaining a favorable safety profile. EDP-323 offers potential as ...
Enanta Pharmaceuticals Reports Positive Topline Results from …
WEBMay 8, 2023 · Dose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to Placebo, Achieving Statistical Significance as Early as One Day After First Dose. No Difference in Viral Load …
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First ...
WEBWATERTOWN, Mass., February 07, 2024 -- (BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology...
Enanta shares hold as Baird affirms target on new data
WEB3 days ago · On Friday, Baird maintained its Outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA), with a steady price target of $26.00. This decision follows the release of new data related to ...
Enanta Pharmaceuticals Reports Financial Results for its Fiscal …
WEBWATERTOWN, Mass., November 20, 2023 -- ( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an...
Enanta Pharmaceuticals Announces Positive Topline Results for …
WEB5 days ago · Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV).